You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ZONE I SOIL DECONTAMINATION THROUGH IN SITU VAPOR STRIPPING PROCESSES

    SBC: Aware, Inc.            Topic: N/A

    THE REMEDIATION OF CONTAMINATED SOILS AND GROUNDS TO ENSURE PROTECTION OF PUBLIC HEALTH AND THE ENVIRONMENT IS DIFFICULTAND COSTLY. THERE IS A CRITICAL NEED FOR THE DEVELOPMENT OFTECHNOLOGIES WHICH ARE BOTH TECHNICALLY SOUND AND COST- EFFECTIVE. THE POTENTIAL REMOVAL OF ROGANIC CHEMICALS FROM UNSATURATED SOILS VIA VAPOR PHASE TRANSPORT APPEARS TO SHOW GREAT PROMISE. THIS APPROACH HAS APPLICABILITY ...

    SBIR Phase II 1987 Environmental Protection Agency
  2. ZONE I SOIL DECONTAMINATION THROUGH IN SITU VAPOR STRIPPING PROCESSES

    SBC: Aware, Inc.            Topic: N/A

    N/A

    SBIR Phase I 1986 Environmental Protection Agency
  3. Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

    SBC: MOLECULAR DESIGN INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A major feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Recent studies from our laboratory have shown that topical treatment ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

    SBC: MOLECULAR DESIGN INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Past studies from our laboratory have shown that topical pretreatment of ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Wheelchair Drive System

    SBC: MAX MOBILITY            Topic: NICHD

    DESCRIPTION (provided by applicant): Wheelchair Drive System Over half of the wheelchair user population has developed upper extremity (UE) pain and injury. One of the activities that likely contribute to the development of injury is wheelchair propulsion. A number of technologies have been developed to address this issue including ergonomic pushrims, geared hub wheels, lever drives and pushrim-a ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Universal Fingerprinting Chips

    SBC: AMERIGENICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The proposed Universal Fingerprinting Chips (UFCs) are microarrays of thousands of oligonucleotide probes designed to interrogate the "sequence space" occupied by essentially any genome or transcriptome. The probe sequences are selected according to specific criteria tailored to the particular application. For example, the probe length will depend on the geneti ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Ultra-Sensitive Molecular Diagnostic for Borrelia Species

    SBC: ATOM SCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The aim of the proposed research is to develop an enabling technology that will allow development of a molecular diagnostic for identification and discrimination among closely related bacterial species that cause signif icant disease at low microorganism numbers. The technology will be advanced through the development of a diagnostic system for detection of spe ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. True Three Dimensional Display For Medical Telepresence

    SBC: Third Dimension Technologies LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase I SBIR project is to demonstrate the feasibility of a high-resolution truly three-dimensional (3D) color display for use in Medical data display applications. Such a display would tremendously improve remote (telepresence) medical teaching, diagnosis, and viewing of three-dimensional kinds of medical data (CT scans, MRI scans, PET scan ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. True Three Dimensional Display For Medical Telepresence

    SBC: Third Dimension Technologies LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase II SBIR project is to develop and build an Engineering Demonstration version of a unique and innovative truly three-dimensional (3D) display for use with 3D Medical data and in Medical Telepresenc e applications. There are presently many pseudo-3D displays - generally stereoscopic/two-view, or projection of one plane at a time on to a vol ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Trimer-Tag: A Technology for Producing Trivalent Biologics

    SBC: GENHUNTER CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): One of the modern strategies for treating autoimmune diseases such as rheumatoid arthritis and psoriasis involves the use of biologic TNF receptor decoys, such as soluble receptors or therapeutic antibodies, to intercept the inflammatory ligand TNF-1, and thus block the pathological activation of its receptors. However, current TNF-1 biologic blockers are all d ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government